<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01030198</url>
  </required_header>
  <id_info>
    <org_study_id>C68-08-S</org_study_id>
    <nct_id>NCT01030198</nct_id>
  </id_info>
  <brief_title>Laser Treatment for Fresh Surgical Scars and Mature Scars</brief_title>
  <official_title>Post-Market, Two-Arm, Single Blind, Controlled Study of the RevLite Electro-optic Q-Switched Neodymium-doped Yttrium Aluminum Garnet (EO QS Nd:YAG) Laser System for the Treatment of Scars</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cynosure, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cynosure, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to measure the effectiveness of the RevLite Laser in the&#xD;
      treatment of both fresh surgical scars and mature/older scars.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor enrollment&#xD;
  </why_stopped>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of Improvement in Scar Appearance, Vascularity, Height, Pliability, Pigmentation and Any Pre-existing Pruritis</measure>
    <time_frame>1 month post final treatment (fresh scars) or 3 and 6 months post final treatment (mature scars)</time_frame>
    <description>The number of participants who experienced improvements in scar appearance, vascularity, height, pliability, pigmentation and any pre-existing pruritis will be counted.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>New Surgical Scars</condition>
  <condition>Scars</condition>
  <arm_group>
    <arm_group_label>Fresh surgical scars</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment of scars</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mature scars</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment of scars</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RevLite (Laser Treatment)</intervention_name>
    <arm_group_label>Fresh surgical scars</arm_group_label>
    <arm_group_label>Mature scars</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Fitzpatrick Skin Type I-VI and either a fresh surgical scar (with sutures still&#xD;
             present [or dissolving sutures within 7 days of surgery for facial scars or within 14&#xD;
             days of surgery for scars on the trunk or extremities) of at least 2cm in length or an&#xD;
             erythematous and/or hypertrophic scar of at least 2cm in length and of greater than or&#xD;
             equal to 18 months in duration&#xD;
&#xD;
          -  Scar is easily divisible into two equal segments for the purpose of the study, or is&#xD;
             bilateral in nature (e.g., inframammary)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant, lactating, or is planning to become pregnant&#xD;
&#xD;
          -  history of cutaneous photosensitization, porphyria, hypersensitivity to porphyrins or&#xD;
             photodermatosis&#xD;
&#xD;
          -  any skin pathology/condition that could interfere with evaluation or requires the use&#xD;
             of interfering topical systemic therapy&#xD;
&#xD;
          -  coagulation disorder or currently using anti-coagulation medication (including but not&#xD;
             limited to heavy aspirin therapy)&#xD;
&#xD;
          -  any condition which, in the investigator's opinion, would make it unsafe for the&#xD;
             subject to participate in the study&#xD;
&#xD;
          -  currently enrolled in an investigational drug or device trial, or has received an&#xD;
             investigational drug or been treated with an investigational device within 30 days&#xD;
&#xD;
          -  unable to communicate or cooperate with the investigator due to language problems,&#xD;
             poor mental development, or impaired cerebral function&#xD;
&#xD;
          -  unreliable for the study, including subjects who engage in excessive alcohol intake or&#xD;
             drug abuse, or subjects who are unable to return for scheduled follow-up visits&#xD;
&#xD;
          -  Isotretinoin therapy within 6 months&#xD;
&#xD;
          -  need to be exposed to artificial tanning devices or excessive sunlight during the&#xD;
             trial&#xD;
&#xD;
          -  prior treatment with parenteral gold therapy&#xD;
&#xD;
          -  does not agree to refrain from other laser treatment, (micro)dermabrasion or topical&#xD;
             scar treatment creams for the duration of the study&#xD;
&#xD;
          -  Diabetes Type 1 or 2&#xD;
&#xD;
          -  Lupus, scleroderma or similar immune system disorder&#xD;
&#xD;
          -  underlying silicone or other non-absorbable filler in the area of the scar&#xD;
&#xD;
          -  phenol chemical peel or dermabrasion to the area of the scar within 3 months&#xD;
&#xD;
          -  Fitzpatrick Skin Type IV, V or VI with a known sensitivity to hydroquinone or is&#xD;
             unwilling or unable to comply with physician/manufacturer instructions for the use of&#xD;
             this ingredient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sanctuary Medical Aesthetic Center</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 10, 2009</study_first_submitted>
  <study_first_submitted_qc>December 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2009</study_first_posted>
  <results_first_submitted>April 26, 2013</results_first_submitted>
  <results_first_submitted_qc>October 26, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 17, 2020</results_first_posted>
  <last_update_submitted>December 16, 2020</last_update_submitted>
  <last_update_submitted_qc>December 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cicatrix</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fresh Surgical Scars</title>
          <description>Device: RevLite (Laser Treatment)</description>
        </group>
        <group group_id="P2">
          <title>Mature Scars</title>
          <description>Device: RevLite (Laser Treatment)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">None recruited</participants>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">None recruited</participants>
                <participants group_id="P2" count="0">Study terminated due to poor results and lack of enrollment</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Could not measure efficacy accurately</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>There were no baseline participants who were analyzed that had fresh surgical scars. This study was not completed due to the lack of enrollment.</population>
      <group_list>
        <group group_id="B1">
          <title>Fresh Surgical Scars</title>
          <description>Treatment of scars&#xD;
Device: Revlite</description>
        </group>
        <group group_id="B2">
          <title>Mature Scars</title>
          <description>Treatment of scars&#xD;
Device: Revlite</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="48.4" spread="10.2"/>
                    <measurement group_id="B3" value="48.4" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Assessment of Improvement in Scar Appearance, Vascularity, Height, Pliability, Pigmentation and Any Pre-existing Pruritis</title>
        <description>The number of participants who experienced improvements in scar appearance, vascularity, height, pliability, pigmentation and any pre-existing pruritis will be counted.</description>
        <time_frame>1 month post final treatment (fresh scars) or 3 and 6 months post final treatment (mature scars)</time_frame>
        <population>Could not measure accurately with measurement tools.</population>
        <group_list>
          <group group_id="O1">
            <title>Fresh Surgical Scars</title>
            <description>Treatment of scars&#xD;
RevLite (Laser Treatment)</description>
          </group>
          <group group_id="O2">
            <title>Mature Scars</title>
            <description>Treatment of scars&#xD;
RevLite (Laser Treatment)</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Improvement in Scar Appearance, Vascularity, Height, Pliability, Pigmentation and Any Pre-existing Pruritis</title>
          <description>The number of participants who experienced improvements in scar appearance, vascularity, height, pliability, pigmentation and any pre-existing pruritis will be counted.</description>
          <population>Could not measure accurately with measurement tools.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events occurring were captured and followed until the study was terminated, approximately 11 months.</time_frame>
      <desc>The number of patients at risk is zero because no patients were enrolled in the fresh surgical study arm.</desc>
      <group_list>
        <group group_id="E1">
          <title>Fresh Surgical Scars</title>
          <description>Treatment of scars&#xD;
Device: Revlite</description>
        </group>
        <group group_id="E2">
          <title>Mature Scars</title>
          <description>Treatment of scars&#xD;
Device: Revlite</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI cannot disclose confidential or proprietary information until after it becomes generally known or available to the public.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to small numbers of subjects analyzed.Technical problems with measurement leading to unreliable or uninterpretable data.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jamie Trimper</name_or_title>
      <organization>Cynosure, Inc.</organization>
      <phone>800-886-2966</phone>
      <email>jamie.trimper@cynosure.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

